Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2017 Aug 19.
Published in final edited form as: Contemp Clin Trials. 2016 Sep 23;51:98. doi: 10.1016/j.cct.2016.09.001

Corrigendum to “Design of the NIDA clinical trials network validation study of tobacco, alcohol, prescription medications, and substance use/misuse (TAPS) tool” [Contemporary Clinical Trials. 2016 Jul. 19; 50: 90–97]

Li-Tzy Wu a,b,c,d,*, Jennifer McNeely e, Geetha A Subramaniam f, Gaurav Sharma g, Paul VanVeldhuisen g, Robert P Schwartz h
PMCID: PMC5562544  NIHMSID: NIHMS890374  PMID: 27665683

In the article, we mistakenly stated that we drew select items from the World Health Organization’s Composite International Diagnostic Interview 2.0 (WHO CIDI-2.0) substance abuse module to assess substance use disorders. However, we actually used select items from the WHO World Mental Health-CIDI [WMH-CIDI]: http://www.hcp.med.harvard.edu/wmhcidi/index.php). Additionally, the DSM-5 has only one set of criteria for all substance use disorders, including tobacco. Because the WMH-CIDI does not contain all the criteria for DSM-5 Tobacco Use Disorder, we adapted the language from the WMH-CIDI items from the drug section to assess tobacco use disorder. Readers of our article should note the mislabeling “modified CIDI-2” in Fig. 1 and on page 95. The correct description should read “modified WMH-CIDI.”

The authors would like to apologise for any inconvenience caused.

RESOURCES